Archives

The Maastricht Aging Study (MAAS) was designed to specify the usual and pathological aging of cognitive function. MAAS is devoted to the age-related decline of memory and other cognitive functions in normal people and the factors that may be involved in this process. What determines a decline in memory function? Why do some individuals show a greater decline than others? Over the past years, a host of factors, including biological, medical, psychological and social variables, have been proposed to have an impact on adult cognitive development. MAAS tries to study these factors in an integrative way. This can be achieved only by studying large numbers of normal healthy adults of all ages and by monitoring them for several years.

The Lifelines Cohort Study is a large population-based cohort study and biobank that was established as a resource for research on complex interactions between environmental, phenotypic and genomic factors in the development of chronic diseases and healthy ageing. The Lifelines cohort distinguishes a children’s cohort (aged 0-18), an adult cohort (aged 18-65) and the elderly cohort (aged 65+). The protocol for these three sub-cohorts is largely the same, but focuses in part on the characteristics of the specific participant groups.

Between 2006 and 2013, inhabitants of the northern part of The Netherlands and their families were invited to participate, thereby contributing to a three-generation design. Follow-up visits are scheduled every 5 years, and in between participants receive follow-up questionnaires. Linkage is being established with medical registries and environmental data. Lifelines contains information on biochemistry, medical history, psychosocial characteristics, lifestyle and more. Genomic data are available including genome-wide genetic data of 15638 participants. Fasting blood and 24-h urine samples are processed on the day of collection and stored at -80 °C in a fully automated storage facility. The aim of Lifelines is to be a resource for the national and international scientific community. Requests for data and biomaterials can be submitted to the Lifelines Research Office ([email protected]).

This project comprises of two complementary parts. One part is aimed at the development of innovative diagnostic techniques to detect molecular signatures of AD based on disturbances of amyloid metabolism and glutamate neurotransmission. In this part, the focus is on the two most promising diagnostic approaches in AD: (molecular) imaging techniques and molecular diagnostic tests of CSF. In the second part of this study, techniques for which proof-of-concept has been found in humans are applied in a large group of AD patients. These patients are recruited in an established network of 4 collaborating memory clinics in The Netherlands, which use a standardized diagnostic protocol and share an extensive common database. Furthermore, more mature molecular, structural, and functional imaging and molecular diagnostic CSF techniques as well as the conventional diagnostic work-up will be applied from the start of the study in patients from the same network of memory clinics.

The Health 2000 Survey, carried out in 2000-2001 in Finland, was coordinated by the National Institute for Health and Welfare, THL (the former National Public Health Institute) in co-operation with an extensive network of organizations and experts. The aim of the survey was to provide information on major public health problems, their causes and treatment, health service needs and utilization as well as functional and working capacity. The data for the survey were collected in comprehensive health examination including blood sampling, in interviews and in self-administered questionnaires. The nationally representative sample included 8,028 persons aged 30 or over of whom 85% participated in the health examination conducted at 80 areas in the mainland Finland. In addition, 1,894 young adults (18-29 years) were invited to the health interview and fill in the questionnaire. Further, 1,278 people who had taken part in Mini-Finland Health Survey carried out in 1978-1980 were invited to the re-examination.

The follow-up of the Health 2000 Survey, the Health 2011 Survey, was carried out in 2011-2012. All members of the Health 2000 sample (n=8,135), who were living in Finland in 2011 and had not refused requests to be invited to further studies, were invited to the Health 2011 Survey. In 2011, they were at least 29 years of age. A total of 59% of them participated in the health examination conducted at 59 areas in Finland. In addition, a new random sample of young adults (aged 18-28, n=1,994) was taken. A total of 415 of them were invited to the health examination and the rest of them (1,579) received only the postal questionnaire. Further, 920 people who had previously taken part in the Mini-Finland Health Survey and invited to re-examination in 2001 were invited.

The Health 2000/2011 cohort is also continuously followed-up by linkage to Finnish nationwide registers.

The Open Access Series of Imaging Studies (OASIS) is a project aimed at making MRI data sets of the brain freely available to the scientific community.

OASIS: Cross-sectional MRI Data in Young, Middle Aged, Nondemented and Demented Older Adults
This set consists of a cross-sectional collection of 416 subjects aged 18 to 96. For each subject, 3 or 4 individual T1-weighted MRI scans obtained in single scan sessions are included. The subjects are all right-handed and include both men and women. 100 of the included subjects over the age of 60 have been clinically diagnosed with very mild to moderate Alzheimer’s disease (AD). Additionally, a reliability data set is included containing 20 nondemented subjects imaged on a subsequent visit within 90 days of their initial session.

OASIS: Longitudinal MRI Data in Nondemented and Demented Older Adults
This set consists of a longitudinal collection of 150 subjects aged 60 to 96. Each subject was scanned on two or more visits, separated by at least one year for a total of 373 imaging sessions. For each subject, 3 or 4 individual T1-weighted MRI scans obtained in single scan sessions are included. The subjects are all right-handed and include both men and women. 72 of the subjects were characterized as nondemented throughout the study. 64 of the included subjects were characterized as demented at the time of their initial visits and remained so for subsequent scans, including 51 individuals with mild to moderate Alzheimer’s disease. Another 14 subjects were characterized as nondemented at the time of their initial visit and were subsequently characterized as demented at a later visit.

Last Update 21/09/2017

Between 1998 and 2002 the Survey team interviewed over 12,583 Southampton women aged 20 to 34 years. Those who became pregnant after interview were invited to take part in the pregnancy phase of the survey. Women received ultrasound scans at 11, 19 and 34 weeks of pregnancy, and their babies were measured soon after birth. There were 3,158 babies born to women in the study between 1998 and 2007. The survey has followed up these children with home visits at six months, one year, two and three years. A sample of over 1,000 children was seen at 4 years of age, more than 2,000 children at ages 6-7 years, and more than 1,000 at 8-9 years. Current follow-up of children at 11-13 years will continue for a number of years.

The aim is to learn more about the dietary,lifestyle, hormonal and omic factors that influence the health of women and their children.

Last Update 21/09/2017

The aim of GS: SFHS is to establish a large, family-based intensively-phenotyped cohort recruited from the general population across Scotland, as a resource for studying the genetics of health areas of current and projected public health importance. It aims to identify genetic variants accounting for variation in levels of quantitative traits underlying the major common complex diseases (such as cardiovascular disease, cognitive decline, mental illness) in Scotland.

Baseline data was collected at a single clinic visit. Longitudinal data is available by linkage to NHS medical records. Some participants are being invited to new clinic visits in 2015-17. This profile also includes scanning information from the Stratifying Resilience and Depression Longitudinally (STRADL) study to which approximately 1500 GS participants are being invited for scanning.

Last Update 21/09/2017

The EADC-PET project (EAPP, The European Alzheimer’s Disease Consortium PET project) is a spontaneous multicentric study (ProtocolDraftSep2008; ProtocolDraftFeb2009) involving at the moment five Centres in four Countries (CENTRES), belonging to the EADC consortium. It was launched during the EADC meeting in Amsterdam, during fall 2007, by Flavio Nobili (Genoa) who is the Principal Investigator.

The project aims at sharing FDG-PET, MRI, neuropsychological, genetic, EEG and clinical information of patients with amnestic Mild Cognitive Impairment (aMCI) and matched healthy controls. Information is uploaded in a safe FTP facility on the server of University of Genoa. Username and password have been provided to all participants. Use of data is regulated by a ‘Confidentiality Disclosure Agreement’ that can be downloaded from this web site (Confidential_Disclosure_Agreement). The Centres propose original studies by sending a formal proposal to all participants who can agree or disagree, or propose modifications/suggestions to the original proposal.

The objective is to follow-up aMCI patients with clinical and neuropsychological examinations to pick up conversion to Alzheimer’s dementia or to other forms of dementia. FDG-PET can be analyzed by means of several post-processing strategies to highlight glucose metabolic information and to identify the characteristics of what is today called ‘prodromal’ AD.

Last Update 21/09/2017

AWHS is a prospective, longitudinal cohort study based on the annual health exams of 5,688 workers of the General Motors Spain automobile assembly plant located in Figueruelas (Zaragoza, Spain). The study was designed to evaluate the trajectories of traditional and emergent cardiovascular diseases (CVD) risk factors (overweight, obesity, high blood pressure, diabetes, smoking, dietary habits or sedentary lifestyle), and their association with metabolic abnormalities and the prevalence and progression of subclinical atherosclerosis in a population of middle-aged men and women in Spain.

The specific aims of AWHS are:

1. To establish the research infrastructure required for a longitudinal cohort study, including setting up a biobank of repeated biological samples to conduct future assays in stored serum, plasma, whole blood, urine and DNA.

2. To identify new genetic, behavioural, and environmental determinants of the progression of adiposity and of the development of metabolic abnormalities and cardiovascular risk factors.

3. To characterize the prevalence and progression of subclinical CVD through non-invasive imaging techniques and their genetic, behavioural, and environmental determinants.

4. To interact with external investigators to promote the use of the study database and stored materials for ancillary studies and to disseminate the study findings to the scientific community, to public health authorities, and to the general public.

To collect data, factory workers undergo a standardized annual clinical exam, providing a clinical history, including clinical events and hospitalizations over the past year and current medication use, and undergo a physical exam, consisting of anthropometry (height, weight, and waist circumference), blood pressure measurements and heart rate, as well as laboratory assays, providing biological samples including serum, plasma, blood, urine and DNA. Data collection at the annual medical exams is conducted by the physicians and nurses of the Medical Services of General Motors Spain, who underwent training and standardization programs organized by the study investigators.

Each year, one random third of study participants 40 ヨ55 years of age at baseline (n=2667) are selected for subclinical atherosclerosis imaging (Cardiac CT for Calcium Scoring, 2D ultrasound of carotid arteries, infrarenal aorta and femoral arteries), and for additional questionnaires of cardiovascular and lifestyle factors (dietary habits, sedentary, physical activity and sleep).

On September 2017, a substudy will begin with the aim of identifying early cognitive impairment in workers over 55 years of age, by using specific questionnaires and gene screening (Apo E).

Workers were excluded from the cohort if they have clinically overt CVD, or a major clinical condition limiting survival to <3 years at baseline. All laboratory procedures have been reviewed and improved to meet the ISO 9001:2008 standard, verified by an external audit.

Last Update 21/09/2017

Alberta’s Tomorrow Project (ATP) is a longitudinal study tracking the health of 55,000 adults aged 35-69 years in this western Canadian province. ATP was launched in 2000 as a prospective cohort research platform to study the relationship between environmental, lifestyle, and genetic factors and the incidence of cancer and chronic diseases.

In 2008, ATP joined a nation-wide research platform called the Canadian Partnership for Tomorrow Project (CPTP) representing more than 300,000 participants from five provincial cohorts: Alberta, British Columbia, Ontario, Quebec and the Atlantic provinces (Prince Edward Island, New Brunswick, Newfoundland and Labrador, and Nova Scotia). Together, the consortium of five regional studies provides greater statistical power for research, as well as opportunities to examine geographical trends in health and wellbeing across Canada’s vast landscape.

The information contained herein is specific to the ATP cohort.

Last Update 21/09/2017